Argos Therapeutics Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

Argos Therapeutics General Information

Description

Developer of personalized immunotherapies designed for the treatment of cancer and infectious diseases. The company utilizes proprietary technology for developing rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and dendritic cell-based immunotherapy for the treatment of human immunodeficiency virus, enabling doctors to improve the patient's immune response to their specific condition.

Contact Information

Formerly Known As
CoImmune
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4233 Technology Drive
  • Durham, NC 27704
  • United States
+1 (919)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 4233 Technology Drive
  • Durham, NC 27704
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Argos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
20. Secondary Transaction - Private Completed Clinical Trials - Phase 2
19. Later Stage VC 01-Jun-2021 Cancelled Clinical Trials - Phase 2
18. Later Stage VC (Series A) 04-Nov-2020 Completed Clinical Trials - Phase 2
17. Merger/Acquisition 13-Feb-2019 Completed Bankruptcy: Admin/Reorg
16. Bankruptcy: Admin/Reorg 30-Nov-2018 Completed Bankruptcy: Admin/Reorg
15. PIPE 28-Jul-2016 Completed Generating Revenue
14. Secondary Transaction - Open Market 23-Mar-2016 Completed Generating Revenue
13. PIPE 14-Apr-2015 Completed Clinical Trials - Phase 2
12. IPO 07-Feb-2014 $45M $274M Completed Clinical Trials - Phase 2
11. Later Stage VC (Series E) 20-Nov-2013 $60M $229M Completed Clinical Trials - Phase 2
To view Argos Therapeutics’s complete valuation and funding history, request access »

Argos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 18,500,000 $0.001000 8% $1.76 $0.56 1x $22.63 1.5%
Series A 1,200,000 $0.001000 8% $1 $0.32 1x $22.63 0.06%
To view Argos Therapeutics’s complete cap table history, request access »

Argos Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of personalized immunotherapies designed for the treatment of cancer and infectious diseases. The company util
Drug Discovery
Durham, NC
15 As of 2024

Plymouth Meeting, PA
 

Flemington, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Argos Therapeutics Competitors (69)

One of Argos Therapeutics’s 69 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Arno Therapeutics Formerly VC-backed Flemington, NJ
Centrose Venture Capital-Backed Madison, WI
Iovance Biotherapeutics Corporation San Carlos, CA
Pure MHC Formerly VC-backed Austin, TX
You’re viewing 5 of 69 competitors. Get the full list »

Argos Therapeutics Patents

Argos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021205502-A1 Methods of treating tumors Inactive 10-Jan-2020
CA-3162074-A1 Methods of treating tumors Pending 10-Jan-2020
EP-4087601-A2 Methods of treating tumors Inactive 10-Jan-2020
US-20230061319-A1 Methods of treating tumors Inactive 10-Jan-2020
WO-2021142305-A2 Methods of treating tumors Inactive 10-Jan-2020 A61K40/46
To view Argos Therapeutics’s complete patent history, request access »

Argos Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Argos Therapeutics Former Investors (35)

Investor Name Investor Type Holding Investor Since Participating Rounds
ABN AMRO Bank Investment Bank Minority
Ascenion Accelerator/Incubator
BD Ventures Corporate Venture Capital Minority
Buenafortuna Capital Venture Capital Minority
Cordova Ventures Venture Capital Minority
You’re viewing 5 of 35 investors. Get the full list »

Argos Therapeutics Acquisitions (1)

Argos Therapeutics’s most recent deal was a Merger/Acquisition with Formula Pharmaceuticals. The deal was made on 16-Jan-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Formula Pharmaceuticals 16-Jan-2020 Merger/Acquisition Drug Discovery
To view Argos Therapeutics’s complete acquisitions history, request access »

Argos Therapeutics FAQs

  • When was Argos Therapeutics founded?

    Argos Therapeutics was founded in 1997.

  • Where is Argos Therapeutics headquartered?

    Argos Therapeutics is headquartered in Durham, NC.

  • What is the size of Argos Therapeutics?

    Argos Therapeutics has 15 total employees.

  • What industry is Argos Therapeutics in?

    Argos Therapeutics’s primary industry is Drug Discovery.

  • Is Argos Therapeutics a private or public company?

    Argos Therapeutics is a Private company.

  • What is Argos Therapeutics’s current revenue?

    The current revenue for Argos Therapeutics is .

  • How much funding has Argos Therapeutics raised over time?

    Argos Therapeutics has raised $45M.

  • Who are Argos Therapeutics’s investors?

    ABN AMRO Bank, Ascenion, BD Ventures, Buenafortuna Capital, and Cordova Ventures are 5 of 35 investors who have invested in Argos Therapeutics.

  • Who are Argos Therapeutics’s competitors?

    Inovio Pharmaceuticals, Arno Therapeutics, Centrose, Iovance Biotherapeutics, and Pure MHC are some of the 69 competitors of Argos Therapeutics.

  • Who acquired Argos Therapeutics?

    Argos Therapeutics was acquired by Genexine and Poongjeon Pharmacy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process